A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. (Q48118406)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Andrew H Briggs

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

3

Ron Akehurst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Sergio Iannazzo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Michael Adena

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Bastian Dehmel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Patrick Parfrey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Vasily Belozeroff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

1 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

603-612

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40273-017-0605-2

14 March 2020

exact match

0 references

cites work

The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease

1 reference

12 December 2020

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

12 December 2020

Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

1 reference

12 December 2020

The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation

1 reference

12 December 2020

Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

1 reference

12 December 2020

The half-cycle correction: banish rather than explain it.

1 reference

12 December 2020

Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods

1 reference

12 December 2020

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data

1 reference

12 December 2020

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

1 reference

12 December 2020

Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy

1 reference

12 December 2020

A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries

1 reference

12 December 2020

Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States

1 reference

12 December 2020

Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs

1 reference

12 December 2020

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.

1 reference

12 December 2020

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

1 reference

12 December 2020

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

1 reference

12 December 2020

Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis

1 reference

12 December 2020

Healthcare use and costs before and after parathyroidectomy in patients on dialysis

1 reference

12 December 2020

Response to "the life table method of half-cycle correction: getting it right".

1 reference

12 December 2020

Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study

1 reference

12 December 2020

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial

1 reference

12 December 2020

Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].

1 reference

12 December 2020

Lag-censoring analysis: lights and shades

1 reference

12 December 2020

International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data

1 reference

12 December 2020

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland

1 reference

12 December 2020

Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design

1 reference

12 December 2020

AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users

1 reference

12 December 2020

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

1 reference

12 December 2020

Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.

1 reference

12 December 2020

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

1 reference

12 December 2020

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

1 reference

12 December 2020

Hemodialysis patients' preferences for the management of secondary hyperparathyroidism

1 reference

12 December 2020

Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD

1 reference

12 December 2020

10.1007/S40273-017-0605-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29392552%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference